News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • EyePoint's Phase 3 program for DURAVYU targets durability and safety outcomes.
  • DURAVYU has received three consecutive positive DSMC recommendations.
  • EyePoint appointed a seasoned ophthalmology commercial chief to lead commercialization efforts.
  • EyePoint reports cash runway extending into Q4 2027.
  • Analyst recommends a long trade with $14 entry, $20 target, and $10 stop.
  • Investment horizon specified at 180 trading days.

Latest Articles

ZJK Industrial Co., Ltd. Advances Localization Strategy in Vietnam to Strengthen Global Production Network

ZJK Industrial Co., Ltd. Advances Localization Strategy in Vietnam to Strengthen Global Production Network

ZJK Industrial Co., Ltd., a NASDAQ-listed high-tech precision parts manufacturer, announced advancement of its localization strategy through its Vietnamese subsidiary, ZJK Vietnam Precision Components Co. The new facility focuses on R&D and production of precision components for sectors like AI infrastructure, electronics, and automotive, aiming to…

Callan JMB Launches The Atlas Complex in Alabama to Successfully Achieve the Capture of Significant Pharmaceutical Onshoring Demand and Expand U.S. Supply Chain Infrastructure

Callan JMB Launches The Atlas Complex in Alabama to Successfully Achieve the Capture of Significant Pharmaceutical Onshoring Demand and Expand U.S. Supply Chain Infrastructure

Callan JMB Inc. announced the development of Atlas Complex, a 150-acre pharmaceutical, medical, and logistics campus in Marion, Alabama. The facility will support pharmaceutical onshoring, early-stage production, QA/QC, cold-chain logistics, and domestic distribution. Partnering with Monarch Property Management and Walker's Pharmaceuticals of India…

Fusion Fuel Highlights Announced Exploration Plan at Jaguar Uranium’s Huemul Project, Potential Royalty Portfolio Income

Fusion Fuel Highlights Announced Exploration Plan at Jaguar Uranium’s Huemul Project, Potential Royalty Portfolio Income

Fusion Fuel Green PLC announced its planned acquisition of a controlling interest in Royal Uranium Inc., which holds a 1.0% NSR royalty on the Huemul Project in Argentina. This strategic move provides Fusion Fuel capital-efficient exposure to uranium, copper, and vanadium resources at a historically significant mining district. Jaguar Uranium's exp…

MainStreet Bancshares, Inc. Announces First Quarter 2026 Results

MainStreet Bancshares, Inc. Announces First Quarter 2026 Results

MainStreet Bancshares, Inc. reported a net income of $4.1 million for Q1 2026, with EPS of $0.48, driven by a 9 basis point expansion in net interest margin to 3.47%. The company executed a buyback of over 273,000 shares, strengthened its capital position, increased net loans to $1.85 billion, and maintained a strong 98% loan-to-deposit ratio. Depo…

Axe Compute Unveils Compute Reserve Dashboard, Giving Investors a Unified View of Its NASDAQ Stock and Operational Strategic Compute Reserve

Axe Compute Unveils Compute Reserve Dashboard, Giving Investors a Unified View of Its NASDAQ Stock and Operational Strategic Compute Reserve

Axe Compute Inc., a NASDAQ-listed AI infrastructure platform, announced the launch of its Strategic Compute Reserve (SCR) Dashboard. The dashboard consolidates detailed, real-time insights into the company's GPU asset reserves and stock metrics, improving transparency by integrating the equity valuation with the value and unlock schedule of its AI …

Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026

Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026

Calidi Biotherapeutics presented new compelling data demonstrating the effectiveness of its RedTail virotherapy platform, which systemically delivers targeted genetic medicines for cancer treatment. The company highlighted its lead candidate CLD-401 and introduced CLD-501 targeting TROP2, aiming to improve T-cell engagers' efficacy in solid tumors …

Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks

Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks

Kyverna Therapeutics reported positive longer-term follow-up data from the Phase 2 portion of its KYSA-6 trial evaluating mivocabtagene autoleucel (miv-cel), a CAR T therapy, in patients with generalized myasthenia gravis (gMG). The data demonstrate rapid, robust, and sustained clinical improvements through 52 weeks after a single dose, with all pa…

BioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart Failure

BioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart Failure

BioCardia announced a favorable outcome from its clinical consultation with Japan's PMDA for CardiAMP Cell Therapy, signaling likely sufficiency of its clinical data to support regulatory approval for ischemic heart failure treatment in Japan. The company is positioned to become the first to offer a minimally invasive biologic therapy for this cond…

Cycurion CEO Kevin Kelly Discusses Operational Execution, Multi‑Year Contract Momentum, and 2026 Growth Priorities in Recent Interview

Cycurion CEO Kevin Kelly Discusses Operational Execution, Multi‑Year Contract Momentum, and 2026 Growth Priorities in Recent Interview

Cycurion, Inc. CEO Kevin Kelly discusses the company's strategic transition towards profitable growth through improved operational execution, cost-saving initiatives, and multi-year contract wins, including a significant government partnership. The company aims to grow revenues substantially in the coming years, overcoming prior challenges related …

Honeywell to Sell Productivity Solutions Unit to Brady for $1.4 Billion

Honeywell to Sell Productivity Solutions Unit to Brady for $1.4 Billion

Honeywell has agreed to divest its productivity solutions and services unit to Brady in an all-cash transaction valued at $1.4 billion. The sale, part of Honeywell’s broader effort to streamline operations ahead of a planned business split, covers a unit that supplies mobile computers, barcode scanners and printing solutions for warehouse and logis…

Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile

Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile

Artelo Biosciences announces publication of peer-reviewed research demonstrating the analgesic potential of its FABP5 inhibitor ART26.12 across multiple pain models, highlighting a differentiated mechanism with a favorable safety profile from Phase 1 studies. The company plans to initiate multiple ascending dose trials later this year to advance cl…

RedCloud to Enter Live Deployment Phase as Combined Turkey and Saudi Joint Ventures Represent Up to $80 Million Revenue

RedCloud to Enter Live Deployment Phase as Combined Turkey and Saudi Joint Ventures Represent Up to $80 Million Revenue

RedCloud Holdings plc is progressing its RAID AI engine from research to live integration within Turkey's leading distribution network, marking a major step towards commercial deployment. This move follows joint ventures in Turkey and Saudi Arabia, collectively valued up to $80 million, reflecting expansion in high-growth FMCG markets amid global s…

Fermi Shares Drop 20% After CEO Steps Down in Broad Leadership Reshuffle

Fermi Shares Drop 20% After CEO Steps Down in Broad Leadership Reshuffle

Fermi Inc. (NASDAQ:FRMI) saw its stock decline roughly 20% on Monday after co-founder Toby Neugebauer stepped down as Chief Executive Officer amid a broader management and governance reorganization the company is calling "Fermi 2.0." The board has appointed Lead Independent Director Marius Haas as Chairman, created an Office of the CEO to preserve …

China Widens Global Push as Tensions with Taiwan and Japan Intensify

China Widens Global Push as Tensions with Taiwan and Japan Intensify

As diplomatic activity in Beijing accelerates amid a spiralling Gulf crisis, China is amplifying both its global diplomatic profile and hard-edged regional manoeuvres. While hosting a stream of high-level visitors and positioning itself as a mediator, Beijing has simultaneously escalated pressure on neighbours - notably Japan, the Philippines and T…

Morgan Stanley Sees Apple as a Tactical Buy Ahead of Earnings

Morgan Stanley Sees Apple as a Tactical Buy Ahead of Earnings

Morgan Stanley analyst Erik Woodring recommends a tactical long position in Apple ahead of its upcoming earnings, projecting small upside for the March quarter and an in-line June quarter EPS driven by revenue resilience despite margin pressure from rising memory costs. The firm highlights supply checks, WWDC and a fall foldable iPhone launch as po…

NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference

NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference

NewcelX Ltd. announced an updated corporate presentation emphasizing its strategic collaboration with Eledon Pharmaceuticals to develop a combined cell therapy and immune-protection approach targeting Type 1 Diabetes. The company's flagship program, NCEL-101, integrates stem-cell-derived islet replacement with Eledon's immune-modulation antibody te…

Nexera: KeepZone AI Enters into White Label Agreement to Develop its AI-Based Voice Communication Decision Support System

Nexera: KeepZone AI Enters into White Label Agreement to Develop its AI-Based Voice Communication Decision Support System

Nexera Technologies Ltd announced that its wholly-owned subsidiary, KeepZone AI Inc., has entered a white label agreement to develop and commercialize an advanced AI-powered real-time voice communication decision support system. This platform aims to enhance operational capabilities in managing multiple voice and radio communication channels simult…